January 16, 2017 9:48 PM ET


Company Overview of TELA Bio, Inc.

Company Overview

TELA Bio, Inc. operates in healthcare industry focusing on biotechnology business. The company was founded in 2012 and is based in Malvern, Pennsylvania.

1 Great Valley Parkway

Suite 24

Malvern, PA 19355

United States

Founded in 2012



Key Executives for TELA Bio, Inc.

President and Chief Executive Officer
Age: 50
Compensation as of Fiscal Year 2016.

TELA Bio, Inc. Key Developments

TELA Bio, Inc. Announces Settlement of Litigation with LifeCell

TELA Bio, Inc. announced that it has settled all litigations and disputes between TELA Bio and LifeCell, and that all pending state and federal court actions between the two companies have been dismissed.  The settlement will allow TELA Bio to continue to manufacture and sell its OviTex ortfolio of products for use in ventral hernia repair and abdominal wall reconstruction, including a hydrated version of OviTex.

TELA Bio, Inc. Presents at 2016 Canaccord Genuity Medical Technology & Diagnostics Forum, Nov-17-2016 10:20 AM

TELA Bio, Inc. Presents at 2016 Canaccord Genuity Medical Technology & Diagnostics Forum, Nov-17-2016 10:20 AM. Venue: Westin Grand Central, 212 East 42nd Street, New York, New York, United States. Speakers: Antony Koblish, President and Chief Executive Officer.

TELA Bio, Inc. Announces OviTex Reinforced BioScaffolds Implanted in 100 Hernia Repair Procedures

TELA Bio, Inc. announced the company's OviTex RBSs have been implanted in more than 100 hernia repair procedures since receiving U.S. Food and Drug Administration (FDA) 510(k) clearance in June 2016. Surgical mesh reinforces soft tissue to improve long-term recurrence rates following hernia repair procedures. Previously, surgeons had to choose between biologic meshes that remodel into a patient's natural tissue, or synthetic meshes that provide strength but introduce a foreign body that results in prolonged inflammation in patients. OviTex RBSs integrate an embedded polymer and an intact extracellular matrix (ECM), a biologic building block derived from ovine rumen, in layered constructs designed for multi-directional cell repopulation and healthy tissue remodeling. The OviTex portfolio includes six products that are available with either permanent (polypropylene) polymer or resorbable (polyglycolic acid) polymer reinforcement.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact TELA Bio, Inc., please visit www.telabio.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.